Event info
Date:09 May
Time:14.30 - 18.00
Venue:Ørestad, Copenhagen
Contact person
Sofia Norås

Sofia Norås

Project Manager

sn@mva.org

+45 2337 0040

MVA R&D Network – Developing and Manufacturing Biologics; From Idea to Market

Medicon Valley Alliance, together with member company Bioneer, have the pleasure to invite you to the Medicon Valley Alliance R&D Network meeting focusing on Biologics Development and Manufacturing on the 9th of May, 2022.

Biologics have paved the way for new treatment paradigms. Dominated by protein and antibody therapeutics, the biologics market now accounts for nearly 20% of the global pharmaceutical market and it continues to grow with the rise of chronic diseases, a rapidly aging population, and the entry of innovative therapies.  As this field grows, new insights into streamlining protein expression, process development, and manufacturing will be key in helping bring biologics to market.

In this MVA R&D network meeting we would like to invite you to hear from speakers in academia and industry who will share their latest developments and insights to help overcome the challenges of taking biologics from idea to active pharmaceutical ingredient.

Date: 9th of May, 2022
Time: 14.30 – 18.00
Venue: Medicon Valley Alliance, Auditorium, Arne Jacobsens Alle 15 , 2300 Ørestad City, Copenhagen
Host: Bioneer

 

SIGN UP

PROGRAM: 


Moderator: Christian Clausen, Chief Scientific officer, Bioneer

14.30 – 15.00 Registration and arrival
15.00 – 15.10Welcome and introduction 
Sofia Norås, Project Manager Networks and events, Medicon Valley Alliance
Christian Clausen, Chief Scientific officer, Bioneer
15.10 – 15.15Intellectual Property Protection for Biologics
Marielle Dejligbjerg, Partner, European Patent Attorney, Høiberg
15.15 – 15.45Keynote speaker – Optimizing Protein Production: Glycosylation, Titer and Development
Bjørn Voldborg, Head of National Biologics Facility, DTU
15.45 – 16.00 Cell line and upstream mAb process development utilizing platform processes
Søren Kofoed Rasmussen, Principal Scientist Process Development, Symphogen
16.00 – 16.15Higher order structure (HOS) assessment of final protein product
Björn Walse, CEO SARomics Biostructures
16.15 – 16.30Short Break
16.30 – 16.45 Cost effective, single-use platform technology for affinity purification in the biopharmaceutical industry
Jan Kyhse-Andersen, CEO, Chreto ApS
16.45 – 17.00An AI immunology platform
Anders Bundgård Sørensen, Director Research and Discovery, Evaxion Biotech
17.00 – 17.15Optimizing expression and purification of early protein product at Bioneer A/S
Christian Clausen, Chief Scientific officer, Bioneer
17.15 – 17.30Q&A and Concluding remarks
17.30 – 18.00Networking

 

Deadline for registration is 4th of May

For more information please contact Sofia Norås sn@mva.org

The MVA R&D Network
The Medicon Valley Alliance R&D Network is a professional and social network for C-level R&D executives (CSOs, CMOs, VPs), university professors and PIs, and top-level managers in the hospital sector. The network focuses on sharing best practice and experiences, as well as discussing current challenges for industry-academia collaboration and the commercialization of R&D in the Medicon Valley region, such as how we can strengthen collaboration and knowledge-sharing between academia and industry to stimulate start-up, scale-up, commercialization and growth and wat is required to turn great science into successful innovations.

Joining the network is free of charge but is limited to Medicon Valley Alliance members. Non-member organizations and companies are welcome to attend one network event to evaluate the relevance in joining the network. For more information please contact Sofia Norås sn@mva.org

 

Host Sponsor of the event 

 

 

MVA R&D Network is managed byIn collaboration with